Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugs

Allard, Per; Eriksson, Kristina; Ross, Svante B.; Marcusson, Jan

doi:10.1007/bf02244092

Cited by 60 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the findings of the current study, most studies have shown that chronic, intermittent cocaine treatment also failed to alter ligand binding to the dopamine transporter (Allard et al 1990;Kula and Baldessarini 1991). A decrease in dopamine transporter density has been associated with chronic cocaine, but only after 10 days of withdrawal (Sharpe et al 1991).…”

Section: Discussionsupporting

confidence: 79%

Chronic administration of the selective dopamine uptake inhibitor GBR 12909, but not cocaine, produces marked decreases in dopamine transporter density

Kunko

Loeloff

Izenwasser

1997

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

The chronic continuous infusion of cocaine produces partial behavioral tolerance to cocaine and tolerance to the inhibition of dopamine uptake by cocaine, without changing dopamine transporter binding. In order to examine more closely the dopaminergic contribution to this effect, the selective dopamine uptake inhibitor GBR 12,909 (30 mg/kg/day), cocaine (50 mg/kg/day), or vehicle, were continuously infused via osmotic minipump, and their effects on the dopamine transporter examined. Drug and vehicle pumps were implanted into male Sprague-Dawley rats and removed after seven days. [3H]WIN 35,428 binding and [3H]dopamine uptake were measured in caudate putamen and nucleus accumbens at varying intervals after pump removal. The Bmax for [3H]WIN 35,428 binding was decreased by approximately 75% in the caudate putamen and by 40% in the nucleus accumbens of GBR 12,909-treated rats both 1 and 4 days after pump removal, and was still significantly decreased after 10 days, but had returned to normal by 20 days post-treatment. In contrast, cocaine did not significantly alter [3H]WIN 35,428 binding. GBR 12,909 produced both tolerance to the inhibition of [3H]dopamine uptake by cocaine, and a decrease in total uptake of dopamine, in the caudate putamen, with no change in the nucleus accumbens. The persistent reduction of [3H]WIN 35,428 binding following continuous GBR 12,909 does not appear to result from residual drug binding. These findings suggest that GBR 12,909 and cocaine may bind to and regulate the dopamine transporter in different ways.

show abstract

Section: Discussionsupporting

confidence: 79%

Chronic administration of the selective dopamine uptake inhibitor GBR 12909, but not cocaine, produces marked decreases in dopamine transporter density

Kunko

Loeloff

Izenwasser

1997

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…The diagnostic cathegory of depression did not influence the results, neither did antidepressant medication nor the method of suicide. Concerning the individuals treated also with neuroleptics, several studies have revealed unchanged binding parameters related to dopamine uptake sites after treatment with these drugs (Allard et al, 1990b;Valchar et al, 1989). It has been shown that striatal dopaminergic D2 receptors are subject to alterations in depression.…”

Section: Discussionmentioning

confidence: 98%

Unchanged density of caudate nucleus dopamine uptake sites in depressed suicide victims

Allard

Norlén

1997

J. Neural Transmission

View full text Add to dashboard Cite

In depressive states, theories concerning serotonin and norepinephrine have been dominating, but there are several lines of evidence indicating the involvement of the dopamine system as well, especially in suicidal depression. In this post-mortem study, the binding of the ligand [3H]WIN 35,428 to dopamine uptake sites in the caudate nucleus was investigated in 13 depressed suicide victims and 19 controls. There were no differences in Bmax or Kd between the suicide group and controls. Subdividing the suicide group into subgroups regarding the presence of major depression, antidepressant medication and suicide method, respectively, did not yield any differences. Previous findings regarding reduced CSF HVA in suicidal depression and indications of striatal dopaminergic biochemical and receptor changes in depression seem, according to the present study, not to be reflected by alterations in density or affinity of dopamine uptake sites in depressed suicide victims.

show abstract

“…Since chronic neuroleptic administration does not affect DAT density (Allard et al 1990;Ase et al 1999;Reader et al 1998;Rivest et al 1995), there was no rationale to withhold treatment prior to the [ ] ␤ -CIT study, eight of the schizophrenic patients were treated with antipsychotic medication at the time of scanning. The other subjects were off-medications for an average of 17.5 Ϯ 11 days (range 7-33 days).…”

Section: Subjectsmentioning

confidence: 99%

The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans

Martínez

Gelernter

Abi‐Dargham

et al. 2001

Neuropsychopharmacology

175

110

View full text Add to dashboard Cite

show abstract

Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugs

Cited by 60 publications

References 20 publications

Chronic administration of the selective dopamine uptake inhibitor GBR 12909, but not cocaine, produces marked decreases in dopamine transporter density

Chronic administration of the selective dopamine uptake inhibitor GBR 12909, but not cocaine, produces marked decreases in dopamine transporter density

Unchanged density of caudate nucleus dopamine uptake sites in depressed suicide victims

The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans

Contact Info

Product

Resources

About